FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3091479370> ?p ?o ?g. }

• W3091479370 endingPage "1862" @default.
• W3091479370 startingPage "1853" @default.
• W3091479370 abstract "To compare tumor best overall response (BOR) by RECIST 1.1 and iRECIST, to explore the incidence of pseudoprogression in melanoma treated with pembrolizumab, and to assess the impact of pseudoprogression on overall survival (OS). A total of 221 patients with locally advanced/unresectable melanoma who received pembrolizumab as part of KEYNOTE-002 trial were included in this study. Radiological assessment of imaging was centrally reviewed to assess tumor response. Incidence of discordance in BOR between RECIST 1.1 and iRECIST as well as rate of pseudoprogression were measured. OS of patients with pseudoprogression was compared with that of those with uncontrolled disease. Of the 221 patients in this cohort, 136 patients developed PD as per RECIST v1.1 and 78 patients with PD continued treatment and imaging beyond initial RECIST 1.1-defined PD. Among the 78 patients who continued therapy and imaging post-progression, RECIST 1.1 and iRECIST were discordant in 10 patients (12.8%) and pseudoprogression was encountered in 14 patients (17.9%). OS of patients with pseudoprogression was longer than that of patients with uncontrolled disease/true progression (29.9 months versus 8.0 months, p value < 0.001). Effectiveness of immunotherapy in clinical trials depends on the criterion used to assess tumor response (RECIST 1.1 vs iRECIST) with iRECIST being more appropriate to detect pseudoprogression and potentially prevent premature termination of effective therapy. Pseudoprogression was associated with improved OS in comparison with that of patients with uncontrolled disease. • Discordance between iRECIST and RECIST 1.1 was found in 12.8% of unresectable melanoma patients on pembrolizumab who continued therapy beyond initial RECIST 1.1-defined progression. • Pseudoprogression, captured with iRECIST, occurred in 17.9% and was significantly associated with improved overall survival in comparison with uncontrolled disease." @default.
• W3091479370 created "2020-10-08" @default.
• W3091479370 creator A5004213202 @default.
• W3091479370 creator A5004914412 @default.
• W3091479370 creator A5008923915 @default.
• W3091479370 creator A5036578095 @default.
• W3091479370 creator A5043090880 @default.
• W3091479370 creator A5045665778 @default.
• W3091479370 creator A5049922238 @default.
• W3091479370 creator A5056132643 @default.
• W3091479370 creator A5058825770 @default.
• W3091479370 creator A5063623733 @default.
• W3091479370 creator A5073322132 @default.
• W3091479370 creator A5086473468 @default.
• W3091479370 creator A5087992328 @default.
• W3091479370 date "2020-09-30" @default.
• W3091479370 modified "2023-10-06" @default.
• W3091479370 title "Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial" @default.
• W3091479370 cites W1809627231 @default.
• W3091479370 cites W2019607817 @default.
• W3091479370 cites W2100129334 @default.
• W3091479370 cites W2100158834 @default.
• W3091479370 cites W2101571970 @default.
• W3091479370 cites W2107484016 @default.
• W3091479370 cites W2296049142 @default.
• W3091479370 cites W2560367415 @default.
• W3091479370 cites W2572174216 @default.
• W3091479370 cites W2590827495 @default.
• W3091479370 cites W2592144107 @default.
• W3091479370 cites W2604241391 @default.
• W3091479370 cites W2625720596 @default.
• W3091479370 cites W2736815193 @default.
• W3091479370 cites W2761586559 @default.
• W3091479370 cites W2770312776 @default.
• W3091479370 cites W2779503684 @default.
• W3091479370 cites W2784235889 @default.
• W3091479370 cites W2792485319 @default.
• W3091479370 cites W2797309423 @default.
• W3091479370 cites W2886088405 @default.
• W3091479370 cites W2912244263 @default.
• W3091479370 cites W2913044136 @default.
• W3091479370 cites W2941142378 @default.
• W3091479370 cites W2963476376 @default.
• W3091479370 cites W3008061706 @default.
• W3091479370 doi "https://doi.org/10.1007/s00330-020-07249-y" @default.
• W3091479370 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32995974" @default.
• W3091479370 hasPublicationYear "2020" @default.
• W3091479370 type Work @default.
• W3091479370 sameAs 3091479370 @default.
• W3091479370 citedByCount "10" @default.
• W3091479370 countsByYear W30914793702021 @default.
• W3091479370 countsByYear W30914793702022 @default.
• W3091479370 countsByYear W30914793702023 @default.
• W3091479370 crossrefType "journal-article" @default.
• W3091479370 hasAuthorship W3091479370A5004213202 @default.
• W3091479370 hasAuthorship W3091479370A5004914412 @default.
• W3091479370 hasAuthorship W3091479370A5008923915 @default.
• W3091479370 hasAuthorship W3091479370A5036578095 @default.
• W3091479370 hasAuthorship W3091479370A5043090880 @default.
• W3091479370 hasAuthorship W3091479370A5045665778 @default.
• W3091479370 hasAuthorship W3091479370A5049922238 @default.
• W3091479370 hasAuthorship W3091479370A5056132643 @default.
• W3091479370 hasAuthorship W3091479370A5058825770 @default.
• W3091479370 hasAuthorship W3091479370A5063623733 @default.
• W3091479370 hasAuthorship W3091479370A5073322132 @default.
• W3091479370 hasAuthorship W3091479370A5086473468 @default.
• W3091479370 hasAuthorship W3091479370A5087992328 @default.
• W3091479370 hasBestOaLocation W30914793702 @default.
• W3091479370 hasConcept C121608353 @default.
• W3091479370 hasConcept C126322002 @default.
• W3091479370 hasConcept C126838900 @default.
• W3091479370 hasConcept C143998085 @default.
• W3091479370 hasConcept C2777701055 @default.
• W3091479370 hasConcept C2779984678 @default.
• W3091479370 hasConcept C2780057760 @default.
• W3091479370 hasConcept C2989005 @default.
• W3091479370 hasConcept C31760486 @default.
• W3091479370 hasConcept C535046627 @default.
• W3091479370 hasConcept C71924100 @default.
• W3091479370 hasConceptScore W3091479370C121608353 @default.
• W3091479370 hasConceptScore W3091479370C126322002 @default.
• W3091479370 hasConceptScore W3091479370C126838900 @default.
• W3091479370 hasConceptScore W3091479370C143998085 @default.
• W3091479370 hasConceptScore W3091479370C2777701055 @default.
• W3091479370 hasConceptScore W3091479370C2779984678 @default.
• W3091479370 hasConceptScore W3091479370C2780057760 @default.
• W3091479370 hasConceptScore W3091479370C2989005 @default.
• W3091479370 hasConceptScore W3091479370C31760486 @default.
• W3091479370 hasConceptScore W3091479370C535046627 @default.
• W3091479370 hasConceptScore W3091479370C71924100 @default.
• W3091479370 hasFunder F4320306080 @default.
• W3091479370 hasIssue "4" @default.
• W3091479370 hasLocation W30914793701 @default.
• W3091479370 hasLocation W30914793702 @default.
• W3091479370 hasLocation W30914793703 @default.
• W3091479370 hasOpenAccess W3091479370 @default.
• W3091479370 hasPrimaryLocation W30914793701 @default.
• W3091479370 hasRelatedWork W2342781363 @default.

• next